VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
Shun Lü, Lin Wu, Hong Jian, Ying Cheng, Q-M. Wang, Jian Fang, Z. Wang, Yang Hu, Meili Sun, L. Han, Liyun Miao, Chunming Ding, Jiuwei Cui, B. Li, X. Li, K. Wang, Shundong Cang, Yueyin Pan, F. Ye, A. Liu
Topics & Concepts
MedicineInternal medicineOncologyPemetrexedInterim analysisClinical endpointChemotherapyBevacizumabProgression-free survivalnon-small cell lung cancer (NSCLC)Lung cancerRandomized controlled trialCisplatinA549 cellLung Cancer Treatments and MutationsRadiomics and Machine Learning in Medical ImagingLung Cancer Diagnosis and Treatment